Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Fluoropyrimidine/Platinum-based First-line Chemotherapy in Metastatic Esophageal Squamous Cell Carcinoma: Prognostic Factor Analysis in 239 Patients

NCT01472419 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT01472419
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01472419 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Fluoropyrimidine/Platinum-based First-line Chemotherapy in Metastatic Esophageal Squamous Cell Carcinoma: Prognostic Factor Analysis in 239 Patients
Lead sponsor
Samsung Medical Center
Phase
Observational
Overall status
Completed
Start date
March 31, 2012
Completion date
March 31, 2013
Enrollment
239 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic esophageal squamous cell carcinoma